Guggenheim cuts price targets on C4 Therapeutics and Damora Therapeutics
Guggenheim lowered its price targets on C4 Therapeutics and Damora Therapeutics while keeping Buy ratings, according to Dow Jones Newswires citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at Guggenheim reduced their price target for C4 Therapeutics shares from $7.00 to $6.00 and kept a Buy rating. The same bank trimmed its target for Damora Therapeutics from $60.00 to $59.00, and that stock also retains a Buy rating. Dow Jones Newswires reported the changes, citing data from Benzinga.
The revisions are modest and concern two separate biotechnology companies.
why it matters
Price target changes from a single bank usually affect only the stocks in question and rarely shift the broader market picture. Company reports and their own news matter more for valuation.
tags
instruments
sources
- C4 Therapeutics Price Target Cut to $6.00/Share From $7.00 by Guggenheim — Dow Jones Newswires, 6 November 2026 at 16:31 UTC
- Damora Therapeutics Price Target Cut to $59.00/Share From $60.00 by Guggenheim — Dow Jones Newswires, 6 November 2026 at 16:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗